LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

EuropaBio presents EFIB Vilnius Statement to European policymakers

30/11/2022
PRESS RELEASE

Today,  EuropaBio hosted the official launch event of the EuropaBio's EFIB Vilnius Statement of 2022, with a round table dedicated to discussion around the role and potential of enabling technologies in the EU green transition. Policy makers, Member States and other stakeholders joined EuropaBio members to drive the discussion. 

The launch reflects the official Statement generated from EuropaBio’s 15th European Forum for Industrial Biotechnology & the Bioeconomy (EFIB) ‘’Next generation economies: industrial biotechnology for a sustainable society’ in Vilnius, Lithuania. 350 delegates from 18 countries worldwide and across multiple sectors gathered to address the economic future for industrial biotechnology, resulting in the Vilnius Statement formally launched in Brussels today.

‘’Today, we are honoured to present the EFIB Vilnius statement to European policymakers, coming at a critical time of current global challenges such as Covid recovery, food supply chain and energy security. Delivering on EU Green Deal objectives whilst strengthening resilience and independence of European industries is essential and industrial biotechnology and biomanufacturing are part of the solution’’, said Dr Claire Skentelbery, Director General of EuropaBio.

The EFIB Vilnius statement set the stage with three industry asks for 2023 and beyond:

  1. Modernalizing regulation and policy: enabling impact

For a cohesive approach across sectors, advanced knowledge on microorganisms should be recognised and considered when developing the policy action for plants developed using NGTs.

 

  1. Education and awareness: enabling citizens

For maximum economic return from advanced technologies, supporting skills should be a priority throughout Europe, integral to all industrial and innovation development.

 

  1. Financing innovation: enabling technologies

The power of industrial biotechnology as an enabling technology should be recognised within financial frameworks to allow a substantial contribution in key economic sectors.

 

The official Vilnius statement presentation was followed by a handover of the document to the European Commission which was presented by Simonas Šatūnas, Head of Cabinet of the Virginijus Sinkevičius, Commissioner for Environment. S. Šatūnas in his follow up remark highlighted the importance to emphasise economic side of the circular economy narrative rather than focusing solely on biodiversity or reduction of the pollution.

The roundtable continued with interventions from IFF, Novozymes, BioPharmaChem Ireland, European Commission representatives and attaches from various national Permanent Representations to the European Union. Discussions revealed a common goal to make Europe a leader in biomanufacturing, reinforce skills and talent development and favourable regulatory environment.

At the end of the meeting, Claire Skentelbery invited participants to continue a discussion on this topic and evaluate the implementation of the Vilnius statement next year, during the next edition of EFIB which will take place in October 24-25, 2023 in Rotterdam, the Netherlands.

EuropaBio presents EFIB Vilnius Statement to European policymakers


Download

Share
Communications Team
Communications Team

Related posts

14/07/2025

EuropaBio Annual Report 2025


Read more
11/07/2025

Industrial Decarbonisation Accelerator Act – EuropaBio Position


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more

Important links

  • Public Consultation Response to the European Commission’s 28th Regime proposal
  • EuropaBio Annual Report 2025

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.